SynthesisAdvances in therapy2026
Multi-omics Approaches for Biomarker Discovery of Uterine Fibroids: A Systematic Review.
Synthesis in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
introductionUterine fibroids are the most common benign gynecological tumors, affecting up to 70-80% of women, yet still lack clinically validated biomarkers for disease stratification, monitoring, or therapeutic targeting. Advances in multi-omics technologies offer unprecedented opportunities for biomarker discovery; however, their application in fibroid research remains fragmented across platforms, biological samples, and study designs, limiting translational progress.
methodsThe PubMed, Embase, and Scopus databases were searched from 2000 to July 15, 2025, to identify relevant studies. Original, peer-reviewed articles using high-throughput omics technologies to discover fibroid-associated biomarkers were included. A narrative synthesis approach was employed to summarize the findings of included studies and map candidate biomarkers to their biological pathways. The methodological quality of the studies was assessed using the QUADOMICS tool. The protocol of this review was registered in PROSPERO platform (registration number CRD420251125813).
resultsThirty‑two studies met the inclusion criteria, including genomics (n = 10, 31.3%), transcriptomics (n = 8, 25.0%), epigenomics (n = 3, 9.4%), proteomics (n = 4, 12.5%), metabolomics (n = 3, 9.4%), and multi‑omics (n = 4, 12.5%) approaches for biomarker discovery of uterine fibroids. Single‑omics designs predominated (87.5%) over integrated multi‑omics (12.5%). Six convergent pathways emerged across the different omics layers-extracellular matrix remodeling, hormone signaling, cell cycle regulation, apoptosis resistance, oxidative stress/metabolism, and genome stability-anchored by recurrent biomarker candidates.
conclusionThis review provides the first systematic synthesis of high-throughput omics-based biomarker discovery in uterine fibroids across multiple biological samples. The convergence of multi‑omics findings on a small set of interconnected pathways supports the view of fibroids as a systems‑level disease and highlights tractable molecular targets that could inform non‑invasive biomarker panels and guide the translation of new pathway‑directed therapeutics beyond surgery. Critical gaps still include insufficient utilization of non-invasive samples, limited integration of multi-omics data, and inconsistent validation. Future research requires large-scale, integrated approaches that prioritize circulating biomarkers for clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.